Victor Yang

Victor Yang

Auto-generated profile, based on publicly available information

Victor Yang

Department of Medicine University of Melbourne Melbourne Victoria Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2023 in Drug Safety
Verified
Journal Article
Open access
PDF file
VYVictor Yang
Victor Yang
TKTue W. Kragstrup
Tue W. Kragstrup
CMChristopher McMaster
Christopher McMaster
PRPankti D Reid
Pankti D Reid
NSNamrata Singh
Namrata Singh
DLDavid Liew
David Liew
Janus kinase inhibitors (JAKi) have enormous appeal as immune-modulating therapies across many chronic inflammatory diseases, but recently this promise has been overshadowed by questions regarding associated cardiovascular and cancer risk emerging from the ORAL Surveillance phase 3b/4 post-marketing requirement randomized controlled trial. In that study of patients with rheumatoid arthritis with existing cardiovascular risk, tofacitinib, the first JAKi registered for chronic inflammatory disease, failed to meet non-inferiority thresholds when compared with tumor necrosis factor inhibitors for both incident major adverse cardiovascular events and incident cancer. While this result was unexpected by many, subsequently published observational data have also supported this finding. Notably, however, such a risk has largely not yet been demonstrated in patients outside the specific clinical situation examined in the trial, even in the face of many studies examining this. Nevertheless, this signal has practically re-aligned approaches to both tofacitinib and other JAKi to varying extents, in other patient populations and contexts: within rheumatoid arthritis, but also in psoriatic arthritis, axial spondyloarthritis, inflammatory bowel disease, atopic dermatitis, and beyond. Application to individual patients can be more challenging but remains important to harness the substantive potential of JAKi to the maximum extent safely possible. This review not only explores the evolution of the regulatory response to the signal, its informing data, biological plausibility, and its impact on guidelines, but also the many factors that clinicians must consider in navigating cardiovascular and cancer risk for their patients considering JAKi as immune-modulating therapy.

4 September 2023 in Expert Review of Clinical Immunology
Verified
Journal Article
Closed access
KTKate Tokareva
Kate Tokareva
PRPankti D Reid
Pankti D Reid
VYVictor Yang
Victor Yang
DLDavid Liew
David Liew
APAlexander C. Peterson
Alexander C. Peterson
NSNamrata Singh
Namrata Singh
Janus kinase inhibitors (JAKi) have dramatically improved the treatment of various autoimmune, and myeloproliferative disorders. Recently concern has arisen regarding their safety in patients with rheumatoid arthritis. Here we provide a comprehensive summary of the major current and emerging JAKi and their indications, address recent studies on comparative safety, and provide insight into their future and use. We emphasize that the application of the research findings on a case-by-case basis should consider a patient's age, comorbidities, disease for which JAKi is being considered, disease activity, the JAKi target(s), alternate treatment options available for the patient, and the planned duration of JAKi. Rheumatologists are used to prescribing therapies in which a risk to benefit assessment is required as well as with screening and monitoring for safety of medications. Thus, rheumatologists are already practiced in applying specific criteria to effectively screen and monitor patients who are candidates for JAKi therapy. Ongoing research will help to clarify any mechanisms underlying differential safety signals between JAK and other therapies, what the balance between risk and efficacy is, who the susceptible subpopulations are, and whether safety signals are shared between different JAKis and across indications.

9 December 2023 in Rheumatology Advances in Practice
Verified
Journal Article
Open access
COClaire E Owen
Claire E Owen
APAurora M T Poon
Aurora M T Poon
BLBonnia Liu
Bonnia Liu
DLDavid Liew
David Liew
LYLee Pheng Yap
Lee Pheng Yap
RBRussell R C Buchanan
Russell R C Buchanan
The impact of modern imaging in uncovering the underlying pathology of PMR cannot be understated. Long dismissed as an inflammatory syndrome with links to the large vessel vasculitis giant cell arteritis (GCA), a pathognomonic pattern of musculotendinous inflammation is now attributed to PMR and may be used to confirm its diagnosis. Among the available modalities, 18F-fluorodeoxyglucose (18F-FDG) PET/CT is increasingly recognized for its high sensitivity and specificity, as well as added ability to detect concomitant large vessel GCA and exclude other relevant differentials like infection and malignancy. This atlas provides a contemporary depiction of PMR’s pathology and outlines how this knowledge translates into a pattern of findings on whole body 18F-FDG PET/CT that can reliably confirm its diagnosis.

12 August 2025 in Australian Prescriber
Verified
Journal Article
Open access
PDF file
SHStephanie Hopkins
Stephanie Hopkins
VYVictor Yang
Victor Yang
DLDavid Liew
David Liew
Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in treating pain and inflammation across a wide range of conditions. Choosing an NSAID requires an understanding of their different risk profiles in the context of individual patients.

1 April 2025 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
JLJessica L. Leung
Jessica L. Leung
BRBelinda De Ross
Belinda De Ross
JGJenny Gianoudis
Jenny Gianoudis
NDNatalie Deeble
Natalie Deeble
VYVictor Yang
Victor Yang
COClaire E. Owen
Claire E. Owen
Objective: We aimed to examine fatigue and sleep disturbance in patients with recently diagnosed polymyalgia rheumatica (PMR) compared to age- and gender-matched controls, including associated characteristics and change over an 18-month follow-up period.Methods: Patients meeting the 2012 European Alliance of Associations for Rheumatology/American College of Rheumatology classification criteria for PMR were prospectively recruited, together with matched controls. Assessments were undertaken 3 months after the commencement of glucocorticoids and again 18 months later. Fatigue was quantified using the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire and the 36-item Short Form Health Survey vitality scale. Sleep was quantified using the Pittsburgh Sleep Quality Index. Other data collected included PMR disease activity, depression, anxiety, and physical function status. All participants underwent body composition by dual-energy x-ray absorptiometry and physical function testing.Results: Thirty-six participants with PMR and 32 controls were included. PMR disease activity was low at both visits. Significantly, more patients with PMR than controls suffered severe fatigue (PMR: 36% and 35% at baseline and follow-up, respectively; controls: 3% at both timepoints). Poor sleep quality also affected more patients with PMR (77% and 84% at baseline and follow-up, respectively) than controls (56% at both timepoints). Higher BMI and fat mass index, anxiety, depression, PMR Activity Score, inflammatory markers, pain, and stiffness were all associated with severe fatigue. There were no significant associations with poor sleep.Conclusion: Patients with PMR experience a disproportionate degree of fatigue and sleep disturbance, which persists almost 2 years after starting treatment. Features associated with fatigue include higher adiposity, psychological comorbidity, and PMR disease activity.

11 July 2025 in Rheumatology
Verified
Journal Article
Open access
JLJessica L Leung
Jessica L Leung
BRBelinda De Ross
Belinda De Ross
JGJenny Gianoudis
Jenny Gianoudis
NDNatalie Deeble
Natalie Deeble
VYVictor Yang
Victor Yang
COClaire E Owen
Claire E Owen
Objectives: To investigate physical function, body composition and frailty in recently diagnosed polymyalgia rheumatica (PMR) compared with controls. Methods: In a prospective cohort study, patients with PMR and age- and sex-matched controls were assessed 3 months after glucocorticoid initiation and 18 months later. Measures included the HAQ-DI, grip strength, gait speed, five times chair stand test, Short Physical Performance Battery (SPPB), maximum limb strength/power, habitual physical activity (by accelerometer) and body composition (by DEXA). Frailty was defined as per Fried’s phenotype. Results: Thirty-six participants with PMR and 32 controls were recruited. Participants with PMR had higher HAQ-DI scores (greater disability) than the controls at both visits (mean difference 0.33 [P < 0.001] and 0.39 [P < 0.001]). At follow-up, female participants with PMR performed more poorly in the chair stand test (mean difference 3.27 [95% CI: 0.69, 5.84], P = 0.02), SPPB (mean difference −1.23 [95% CI: −2.01, −0.45], P = 0.003) and gait speed (mean difference −0.24 [95% CI: −0.36, −0.12], P < 0.001) than the controls. Between timepoints, female participants with PMR had greater decline in gait speed than the controls (mean difference −0.13 [95% CI: −0.23, −0.03], P = 0.009). No significant differences for change in body composition were found. Pre-frailty rates were higher in participants with PMR than the controls (71.2% vs 34.4% (odds ratio 4.7 [P = 0.003]) and 60.7% vs 34.4% (odds ratio 2.9 [P = 0.04]) at the initial and follow-up visits, respectively). Conclusion: PMR has a lasting impact on physical function, particularly in females. These findings highlight the need for routine physical function assessments and targeted muscle conditioning measures in PMR management.